InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.43 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
InflaRx N.V. [IFRX]
Reports for Purchase
Showing records 41 - 51 ( 51 total )
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Topline Phase 3 Vilobelimab Data in COVID-19 Expected by Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 2 Trial of Vilobelimab in Cutaneous Squamous Cell Carcinoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Vilobelimab Shown to be Safe and Well Tolerated in Phase 2 IXPLORE Study in AAV Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Interim Analysis for Vilobelimab in COVID-19 Expected in 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Target Enrollment Reached in Phase 2a Trial of Vilobelimab for Pyoderma Gangraenosum Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
4Q20 Results; Data for Vilobelimab in COVID-19 Expected This Year; Lower PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
New C5a and Vilobelimab Data Presented Supporting Continued Development in Hidradenitis Suppurativa
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Vilobelimab Development Update; Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Complete Enrollment Announced for the European Phase 2 IXCHANGE Study of Vilobelimab in AAV
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E